E. Linderoth

发表

TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets

V. Lee, Tran Truong, M. Wong, 2017, PloS one.

Lysosome-mediated apoptosis is associated with cathepsin D-specific processing of bid at Phe24, Trp48, and Phe183.

B. Antonsson, Hanna Appelqvist, R. Steinfeld, 2012, Annals of clinical and laboratory science.

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

S. Trudel, J. Koropatnick, S. Viau, 2016, Clinical Cancer Research.

Signal requirement for cortical potential of transplantable human neuroepithelial stem cells

M. Zhen, B. Varga, A. Nagy, 2021, Nature Communications.

Mig6 Is a Sensor of EGF Receptor Inactivation that Directly Activates c-Abl to Induce Apoptosis during Epithelial Homeostasis

G. Superti-Furga, O. Hantschel, M. Smalley, 2012, Developmental cell.

Abstract 2646: Intratumoral delivery of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, inhibits tumor growth and prolongs animal survival in a subcutaneous B cell lymphoma model

G. Lin, L. D. Johnson, Bolette Bossen, 2017 .

Abstract 2653: The anti-myeloma activity of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, is enhanced when combined with a proteasome inhibitor

V. Lee, G. Lin, L. D. Johnson, 2017 .

Activated Cdc42-associated Kinase 1 (Ack1) Is Required for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor Recruitment to Lipid Rafts and Induction of Cell Death*

N. Mahajan, I. Ferby, E. Linderoth, 2013, The Journal of Biological Chemistry.

Abstract 2709: TTI-622 (SIRPα-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with antitumor antibodies in both hematologic and solid tumor models

J. Koropatnick, R. Figueredo, S. M. Vareki, 2018, Immunology.